What does the evidence say about Luteolin Cognition Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Luteolin Cognition Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Figure 1 Thus, in the present review we aimed to summarize the preclinical and clinical evidence of selected nutraceuticals, focusing on biotin, flavonoids especially luteolin, folic acid, Huperzine A, Lion’s mane, olive oil polyphenols (oleuropein and hydroxytyrosol [HT]), and palmitoylethanolamide (PEA). [Venetsanaki Vasiliki (2026); evidence level 3] - The present narrative review highlights current mechanistic insights, as well as evidence from experimental and clinical studies regarding their potential roles in supporting cognitive function, modulating neuroinflammation, and mitigating neurodegenerative processes. [Venetsanaki Vasiliki (2026); evidence level 3] - It should be noted that the present work consists of a review and not a dosing guideline. [Venetsanaki Vasiliki (2026); evidence level 3] - 1 1 Brain health is a multidimensional and evolving concept that is difficult to evaluate and quantify []. [Venetsanaki Vasiliki (2026); evidence level 3] - Increasing evidence implicates neuroinflammation, oxidative stress, and dysregulation of neurotrophic and neurotransmitter systems as central mechanisms driving these conditions. [Rosas-Sánchez GU (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.